EU MDR Verpackungsanforderungen: Vollständiger Compliance-Leitfaden für Hersteller

EU MDR and Sterile Medical Device Packaging

EU Regulation 2017/745 — the Medical Devices Regulation (MDR) — establishes the regulatory framework for medical devices placed on the European market. For manufacturers of sterile devices, the MDR imposes specific requirements on packaging design, material qualification, validation, and labeling that are substantially more rigorous than those that existed under the predecessor Medical Devices Directive (MDD 93/42/EEC).

Packaging for sterile medical devices must satisfy two distinct regulatory obligations under MDR: it must demonstrate biological safety (maintaining sterility to the point of use) and it must carry the correct labeling information to enable safe use and traceability. Both obligations are defined in Annex I — the General Safety and Performance Requirements (GSPRs) — and elaborated in the MDR's labeling provisions.

Understanding precisely what MDR requires for packaging — and how harmonized standards like ISO 11607 map onto those requirements — is essential for manufacturers preparing technical documentation, responding to notified body queries, and planning validation programs in the 2025–2028 transition period.

Annex I GSPR: Packaging Requirements

MDR Annex I contains the General Safety and Performance Requirements that all medical devices must meet before CE marking. Several GSPRs directly apply to packaging systems for sterile devices.

GSPR 11: Devices Supplied in Sterile Condition

GSPR 11.1 states: "Devices labelled as having a specific microbial state shall be designed, manufactured and packaged to ensure that they remain in that state when placed on the market and remain so under the transport and storage conditions specified by the manufacturer." This is the primary packaging requirement — it requires a risk-based demonstration that the sterile barrier system maintains its integrity under all reasonably foreseeable conditions from manufacture to point of use.

GSPR 11.2 requires that the packaging system for sterile devices allows for sterilization in accordance with the manufacturer's processing instructions. This is particularly relevant for re-sterilizable devices and for devices sold unsterilized for sterilization by the healthcare facility.

GSPR 13: Packaging and Environmental Protection

GSPR 13 addresses the requirement that devices be designed, manufactured, and packaged to minimize risk from contaminants and residues. For sterile packaging, this requires that packaging materials do not introduce extractable substances above biocompatibility thresholds, do not generate particulate contamination, and do not degrade in a way that compromises product safety over the stated shelf life.

GSPR 14: Shelf Life and Ageing

GSPR 14 requires that the performance characteristics of a device are not adversely affected to such a degree that health or safety of the patient or user are compromised within the stated shelf life. For packaging, this translates to a requirement for validated shelf life evidence — either real-time aging or accelerated aging per ASTM F1980, with real-time confirmation ongoing. For the full methodology, see the ASTM F1980 accelerated aging guide.

Harmonized Standards: ISO 11607 Under MDR

The European Commission maintains the Official Journal list of harmonized standards under the MDR. EN ISO 11607-1:2020/A1:2023 and EN ISO 11607-2:2020/A1:2023 are both listed harmonized standards for sterile medical device packaging. For a detailed breakdown of ISO 11607's structure and requirements, see the complete ISO 11607 compliance guide.

Application of these harmonized standards gives manufacturers a presumption of conformity with the GSPRs they cover — specifically GSPR 11.1, 11.2, 13, and aspects of 14. This presumption significantly streamlines the evidence burden in technical documentation and notified body review, since the standards provide a well-understood, auditable compliance pathway.

When a manufacturer deviates from a harmonized standard, MDR Article 8 requires that the technical documentation demonstrate equivalent safety and performance using an alternative approach. For packaging, this is rarely necessary — ISO 11607 is comprehensive and widely adopted globally, and its requirements map closely onto MDR outcomes.

Technical Documentation Requirements

MDR Annex II defines the content requirements for technical documentation that manufacturers must compile and maintain. For sterile devices, packaging-related content is required across several sections of the technical documentation structure.

Section 4: Design and Manufacturing Information

This section must include complete information about the packaging system: materials specifications, supplier qualifications, packaging system design drawings or specifications, and any design changes with associated change control documentation. For blister packaging, this includes the forming web specification (e.g., PETG grade, thickness, supplier), lidding material specification (e.g., Tyvek 1073B), and heat-seal adhesive or coating if applicable.

Section 5: GSPR Checklist and Evidence

The GSPR checklist must map each applicable GSPR to the evidence demonstrating conformity. For packaging, the applicable standards (ISO 11607-1, -2) must be cited with the specific clauses addressed, and the corresponding test reports and validation summaries referenced. Notified bodies will scrutinize the completeness of this mapping during technical documentation review.

Packaging Validation Reports

Full validation reports must be included in or referenced from the technical documentation. This includes: IQ/OQ/PQ validation reports for all sealing processes; distribution simulation test reports (ASTM D4169 or equivalent); accelerated aging study results with real-time confirmation plan; seal integrity test reports (including methods used, acceptance criteria, and results); and biocompatibility assessment for all packaging materials in contact with the device or its sterile pathway.

The seal integrity testing method selection guide provides a framework for selecting the appropriate test methods and acceptance criteria for your packaging configuration.

Labeling Requirements for Sterile Packaging

MDR Section 23 establishes labeling requirements, with Section 23.3 specifically addressing the information required on packaging that maintains the sterile condition of a device. This is distinct from the device label itself and applies to the sterile barrier system (and any secondary packaging that maintains sterility).

MDR Transition Timeline and Packaging Validation

Under Regulation (EU) 2023/607 (the MDR Corrigendum extension), devices certified under MDD can continue to be placed on the market under the following transitional provisions:

• Class III and Class IIb implantable devices: until May 26, 2027
• Most Class IIb, IIa, and Class Im/Is/Ir devices: until May 26, 2028

Importantly, these transitional provisions apply to existing MDD certificates — they do not delay the requirement for MDR-compliant technical documentation when seeking new MDR certification. Manufacturers applying for MDR certificates must demonstrate full GSPR compliance, including complete packaging validation evidence, regardless of when they submit.

For packaging validation specifically, the December 20, 2026 FDA deadline for ISO 11607-1:2019 (AMD1:2023) aligns this as a natural checkpoint. Manufacturers conducting EU MDR packaging validation in 2025–2026 should ensure they are working to the current harmonized standard version (EN ISO 11607-1:2020/A1:2023) to satisfy both FDA and MDR requirements simultaneously.

MDR vs. MDD: Key Packaging Differences

Häufig gestellte Fragen

Does EU MDR require real-time aging data before placing sterile devices on the market?

MDR does not explicitly require real-time aging data at time of initial placement on the market, and the harmonized standard (ISO 11607-1) permits accelerated aging as initial evidence provided real-time confirmation is ongoing. However, notified bodies increasingly require a credible real-time aging plan with defined checkpoints in the technical documentation, and PMCF activities must include monitoring of packaging integrity over the product lifecycle.

Which section of MDR Annex II covers packaging validation?

Packaging validation evidence is primarily documented under Annex II Section 6 (Information on design and manufacture), Section 4.5 (sterility, pyrogen status), and Section 5 (the GSPR conformity table). The validation reports themselves may be held as supporting documents referenced from the core technical documentation structure.

Is Tyvek packaging still compliant under EU MDR?

Yes. Tyvek (DuPont) remains a widely used and fully compliant lidding material under EU MDR when used within a validated packaging system meeting EN ISO 11607-1. The material must be qualified per the standard's material characterization requirements, and its sterilization compatibility must be documented for the specific sterilization method used. For detailed grade information, see the Tyvek medical packaging guide.

What is the difference between EU MDR and EU IVDR packaging requirements?

EU MDR (2017/745) applies to medical devices; EU IVDR (2017/746) applies to in vitro diagnostic medical devices. Both regulations impose similar packaging requirements for sterile products — maintaining sterility to the point of use, labeling of the sterile barrier, and compliance with EN ISO 11607. IVDR GSPR 20.3 additionally requires that manufacturers identify which packaging layer constitutes the sterile barrier, using the specific oval-shaped symbols introduced in ISO 15223-1:2021.

Do packaging changes require a new MDR certificate?

Significant packaging changes — such as a change in sterile barrier materials, sealing process, or shelf life — typically require notified body notification and may require a certificate amendment or new certificate depending on the device classification and the nature of the change. Minor changes supported by equivalence data and change control documentation may not require notified body involvement, but the change control assessment must be documented in the technical documentation. Manufacturers should define their change control classification criteria in their quality management system and apply them consistently.

How does the EU PPWR (2026) interact with MDR packaging requirements?

The EU Packaging and Packaging Waste Regulation (effective August 2026) introduces recyclability requirements for all packaging placed on the EU market. Medical device packaging is subject to these requirements, though safety-critical exemptions are under development. Where recyclability cannot be achieved without compromising sterile barrier performance, manufacturers will need to document the safety justification. The interaction between PPWR, MDR, and ISO 11607 is an active area of regulatory guidance development.

Externe Quellen: EU MDR 2017/745 (EUR-Lex) · ISO 11607-1:2019 (ISO.org)